The One-carbon Therapeutics team is proud and excited to share our latest paper published in
Nature Metabolism describing the detailed mode of action of our potent MTHFD1/2 inhibitor
TH9619 under development for difficult-to-treat cancers. It explains the inhibitor’s cancer specificity
and emphasises the importance of utilising correct human-like conditions and cancer models in drug
development. We show that cancer-specific formate overflow drives toxic folate trapping upon
inhibition of cytosolic MTHFD1, leading to cancer cell death.
One-carbon Therapeutics Announces Strategic Collaboration with Tempus to Advance Molecular Insights and Enable Precision Oncology Development of TH9619
Solna, Sweden, March 17h, 2026. One-carbon Therapeutics, a clinical-stage oncology
